Chidamide (Epidaza)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 22:12, 13 June 2018 by Warner-admin (talk | contribs) (Text replacement - "Category:Drug index" to "Category:Drugs")
Jump to navigation Jump to search

Mechanism of action

HDAC inhibitor

Preliminary data

Peripheral T-cell lymphoma

  1. Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Aug;26(8):1766-71. Epub 2015 Jun 23. link to original article PubMed

History of changes in FDA indication

Not FDA approved, but is approved for use in China.

Also known as

  • Code name: HBI-8000
  • Brand name: Epidaza